University of Virginia Patent Foundation

Pgxhealth, LLC

Dogwood Pharmaceuticals, Inc.

Verrica Pharmaceuticals Inc.

Adenosine Therapeutics, LLC

Forest Laboratories Holdings Limited

Emory University

Trovis Pharmaceuticals, LLC

Jayson Michael Rieger

Robert Douglas Thompson

Joel M Linden

Guoquan Wang

Gail W Sullivan

Timothy L MacDonald

Robert Alan Figler

Lauren J Murphree

Anthony Beauglehole

Matthew Gene Davidson

Eugene R Scavola

Frank Schmidtmann

Paul Daly

Howard Welgus

Donald L Kimpel

Shanthi V Sitaraman

Onno Kranenburg

Yuesheng Jason Li

Jarmila Van Der Bilt

Kori Wallace

Inne Borel Rinkes

Frank W Schmidtmann

Eugene Scavola

Lauren Murphree Mihalcik

Applicator devices (), kits, systems, and methods of using such devices for treating one or more body surface conditions (e.g., warts, Molluscum contagiosum, conjunctivitis, otitis) are provided. The applicator device facilitates topical administration of a controllable amount of a pharmaceutical composition to a desired area of an affected body surface (e.g., skin, eye, ear, nose, mouth, anus, vagina). The applicator device includes an ampule () containing the pharmaceutical composition, the ampule being positioned within a tube (). Squeezing the tube breaks the ampule, releasing the pharmaceutical composition. The applicator device includes a filter () that permits passage of fluid and inhibits passage of broken ampule shards. The applicator device includes a dispensing tip () through which the pharmaceutical composition passes.

Devices and methods for the treatment of body surface disorders

Methods of treating one or more skin lesions using cantharidin as well as associated compositions, treatment regimens, kits, devices, and systems are provided. A method of treating a subject having one or more skin lesions may involve administering a composition comprising cantharidin to one or more skin lesions. The method may allow for the efficacious treatment of the skin lesion(s) with minimal or no adverse side effects (e.g., severe adverse side effects, permanent damage of the dermal tissue, scarring, excessive blistering of skin surrounding the lesion, elevated plasma cantharidin concentration, systemic exposure to cantharidin). The efficacy and/or safety of the treatment may be due, to certain features of the composition and/or prolonged exposure of the skin lesion(s) to cantharidin. The methods described herein may be used for a wide variety of cutaneous disorders, including skin disorders that primarily affect the epidermis of skin.

Treatment of cutaneous disorders

Applicator

The present invention relates to a method for treating recurrent tumor metastases following liver resection that includes administration of an effective amount of an agonist of Aadenosine receptors (ARs).

[object Object]

The present invention provides compounds and pharmaceutical compositions that are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates.

Methods for the synthesis of unsymmetrical cycloakyl substituted xanthines

The present invention provides compounds and pharmaceutical compositions that are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates such as: wherein:

Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines

The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

Provided herein are alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof and pharmaceutical compositions containing the same that are selective agonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines such as the following: and pharmaceutical compositions that are selective antagonists of Aadenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.

Substituted 8-[6-amino-3-pyridyl]xanthines

Aagonists of formula (I) is provided, wherein R, R, R, R, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).

Substituted aryl piperidinylalkynyladenosines as A2AR agonists

The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of Aadenosine receptors (ARs).

Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease

The present invention is a method for treatment or prevention of injury to nerve cells. The method can use at least one Areceptor modulator to prevent injury to or enhance the healing of the injured cells.

Growing community of inventors

Charlottesville, VA, United States of America

Jayson Michael Rieger